Thrombin Market

By Product;

Bovine Thrombin, Human Thrombin and Recombinant Thrombin

By Dosage Form;

Powder Forms, Solution Forms and Others

By Application;

Hemostasis, Diagnostics, Research, and Others

By End User;

Hospital, Diagnostics Centers & Clinics and Academics & Research Institutes

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn123236247 Published Date: August, 2025 Updated Date: September, 2025

Thrombin Market Overview

Thrombin Market (USD Million)

Thrombin Market was valued at USD 662.22 million in the year 2024. The size of this market is expected to increase to USD 886.94 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.3%.


Thrombin Market

*Market size in USD million

CAGR 4.3 %


Study Period2025 - 2031
Base Year2024
CAGR (%)4.3 %
Market Size (2024)USD 662.22 Million
Market Size (2031)USD 886.94 Million
Market ConcentrationHigh
Report Pages326
662.22
2024
886.94
2031

Major Players

  • Takeda
  • Bayer
  • CSL
  • Grifols
  • GE Healthcare
  • Hualan Biological
  • Haematologic Technologies Inc.
  • Pfizer
  • Octapharma
  • Omrix Biopharmaceuticals Ltd.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Thrombin Market

Fragmented - Highly competitive market without dominant players


The Thrombin Market is witnessing steady growth fueled by its crucial role in surgical care and wound management. As a central enzyme in the clotting cascade, thrombin plays an essential part in preventing excessive blood loss during medical interventions. Around 55% of its demand is linked to surgical hemostasis, underlining its clinical importance. The rise in surgical procedures and the focus on advanced patient care continue to strengthen its adoption.

Rising adoption in surgical applications
The demand for thrombin in surgery is increasing as it ensures effective clot stabilization and faster recovery. Over 60% of operations utilize thrombin-integrated hemostatic products, reinforcing its value in enhancing surgical precision and safety. Its widespread preference highlights the growing reliance on advanced hemostatic agents in healthcare systems.

Technological advancements in formulations
Ongoing innovations in thrombin-based therapies, including sprays, gels, and combination delivery systems, are transforming the market. Almost 35% of new product developments center around advanced release mechanisms that improve treatment outcomes. These advancements provide greater convenience and better adherence, boosting patient recovery and clinical efficiency.

Future outlook and market expansion
The thrombin market is expected to witness steady growth with expanding clinical usage and rising investments in research. Over 45% of healthcare professionals indicate an increased reliance on thrombin during surgical and emergency care, strengthening its position in medical protocols. The market’s future outlook is marked by innovation, expansion, and stronger integration into healthcare practices.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Dosage Form
    3. Market Snapshot, By Application
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Thrombin Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Growing Surgical Procedures
        2. Rising Demand Worldwide
        3. Technological Advancements
        4. Increasing Healthcare Expenditure
        5. Surge in Trauma Cases
      2. Restraints
        1. Stringent Regulatory Approvals
        2. High Cost of Production
        3. Risk of Blood-Borne Infections
        4. Limited Awareness
        5. Competition from Alternatives
      3. Opportunities
        1. Advancements in Biotechnology
        2. Strategic Collaborations and Partnerships
        3. Increasing R&D Investments
        4. Market Expansion in Developing Regions
        5. Focus on Emerging Applications
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Thrombin Market, By Product, 2021 - 2031 (USD Million)
      1. Bovine Thrombin
      2. Human Thrombin
      3. Recombinant Thrombin
    2. Thrombin Market, By Dosage Form, 2021 - 2031 (USD Million)
      1. Powder Forms
      2. Solution Forms
      3. Others
    3. Thrombin Market, By Application, 2021 - 2031 (USD Million)

      1. Hemostasis

      2. Diagnostics

      3. Research

      4. Others

    4. Thrombin Market, By End User, 2021 - 2031 (USD Million)
      1. Hospital
      2. Diagnostics Centers & Clinics
      3. Academics & Research Institutes
    5. Thrombin Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Takeda
      2. Bayer
      3. CSL
      4. Grifols
      5. GE Healthcare
      6. Hualan Biological
      7. Haematologic Technologies Inc.
      8. Pfizer
      9. Octapharma
      10. Omrix Biopharmaceuticals Ltd.
  7. Analyst Views
  8. Future Outlook of the Market